Skip to main content

Table 2 Baseline characteristics of study population

From: Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Study name

Age (Years), Mean (SD)

Gender, Male, N (%)

History of any preventive treatment use, N (%)

History of any preventive treatment failure, N (%)

Migraine Duration (Years), Mean (SD)

Erenumab 70 mg

Erenumab 140 mg

Placebo

Erenumab 70 mg

Erenumab 140 mg

Placebo

Erenumab 70 mg

Erenumab 140 mg

Placebo

Erenumab 70 mg

Erenumab 140 mg

Placebo

Basedau et al. 2024 [17]

39.1 (12.77)

N/A

41.58 (11.43)

6 (15)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Filippi et al. 2023 [35]

N/A

48·1 (8·83)

42·6 (11·31)

5 (12.82)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Yu et al. 2022 (The DRAGON Study) [29]

41.4 (10.9)

N/A

41.9 (10.9)

103 (18.5)

171 (61.29)

N/A

178 (64.03)

80 (28.67)

N/A

74 (26.62)

18.2 (11.9)

N/A

17.8 (11.4)

Chowdhury et al. 2022 [32]

34.9 (9.2)

35.4 (7.2)

35.3 (8.9)

74 (21.1)

N/A

N/A

N/A

N/A

N/A

N/A

6.76 (5.96)

6.66 (6.54)

6.87 (5.69)

Wang et al. 2021 (The EMPOwER Study) [27]

37.3 (10.0)

37.1 (9.6)

38.0 (10.1)

163(18.11%)

181 (53.6)

119 (53.1)

179 (53.0)

108 (32.0)

72 (32.1)

108 (32.0)

11.1 (9.5)

11.2 (9.7)

12.6 (10.2)

Takishema et al. 2021 [25]

44.2 (8.5)

N/A

44.6 (9.3)

34(13.02%)

60 (46.2)

N/A

50 (38.2)

59 (45.4)

N/A

58 (44.3)

N/A

N/A

N/A

Lanteri-Minet et al. 2021 [21]

N/A

44·6 (10·5)

44·2 (10·6)

46 (18.7)

N/A

N/A

N/A

N/A

121 (100)

125 (100)

N/A

N/A

N/A

Hirata et al. 2021 [19]

44.0 (8.2)

N/A

44.5 (9.6)

25 (14.79)

N/A

N/A

N/A

37 (41.1)

N/A

30 (38.0)

17.71 (11.48)

N/A

18.9 (11.98)

Diener et al. 2021 [33]

41.1 (11.3)

40.4 (11.1)

41.3 (11.2)

141 (14.76)

133 (42.0)

124 (38.9)

131 (41.1)

127 (40.1)

116 (36.4)

127 (39.8)

19.80 (12.26)

19.72 (12.31)

20.05 (12.18)

Broessner et al. 2020 [30]

41.1 (11.3)

40.4 (11.1)

41.3 (11.2)

141 (14.76)

133 (42.0)

124 (38.9)

131 (41.1)

127 (40.1)

116 (36.4)

127 (39.8)

N/A

N/A

N/A

Goadsby et al. 2019 [18]

41.1 (11.3)

40.4 (11.1)

41.3 (11.2)

141 (14.76)

133 (42.0)

124 (38.9)

131 (41.1)

127 (40.1)

116 (36.4)

127 (39.8)

19.80 (12.26)

19.72 (12.31)

20.05 (12.18)

Brandes et al. 2019 [28]

41.4 (11.3)

42.1 (11.3)

42.1 (11.3)

115 (17.2)

138 (72.3)

138 (72.3)

218 (76.2)

127 (66.5)

126 (66.3)

200 (70.0)

N/A

N/A

N/A

Sakai et al. 2019 [23]

43 (8.45)

44.25 (7.86)

43 (7.68)

63 (15.44)

80 (59.3)

77 (56.2)

76 (55.9)

43 (48.9)

54 (65.1)

44 (53.0)

N/A

N/A

N/A

Reuter et al. 2018 (LIBERTY) [22]

N/A

44·6 (10·5)

44·2 (10·6)

46 (18.7)

N/A

N/A

N/A

N/A

121 (100)

125 (100)

N/A

N/A

N/A

Ashina et al. 2018 [16]

41.4 (11.3)

42.1 (11.3)

42.1 (11.3)

115 (17.2)

138 (72.3)

138 (72.3)

218 (76.2)

127 (66.5)

126 (66.3)

200 (70.0)

20.7 (12.9)

21.9 (11.8)

22.2 (12.7)

Buse et al. 2018 [31]

41.1 (11.3)

40.4 (11.1)

41.3 (11.2)

141 (14.76)

133 (42.0)

124 (38.9)

131 (41.1)

127 (40.1)

116 (36.4)

127 (39.8)

19.80 (12.26)

19.72 (12.31)

20.05 (12.18)

Dodick et al. 2018 [34]

42 (11)

N/A

42 (12)

85 (14.7)

134 (46.9)

N/A

132 (45.4)

117 (87.3)

N/A

115 (87.1)

22 (13)

N/A

20 (12)

Goadsby et al. 2017 (STRIVE Study) [36]

41.1 (11.3)

40.4 (11.1)

41.3 (11.2)

141 (14.76)

133 (42.0)

124 (38.9)

131 (41.1)

127 (40.1)

116 (36.4)

127 (39.8)

19.80 (12.26)

19.72 (12.31)

20.05 (12.18)

Tepper et al. 2017 [26]

41·4 (11·3)

42·9 (11·1)

42·1 (11·3)

115(17.24%)

N/A

N/A

N/A

127 (67%

126 (66%)

200 (70%)

20.7 (12.8)

21.9 (11.8)

22.2 (12.6)

Hoon et al. 2017 [20]

N/A

23.8 (5.85)

28.5 (11.7)

3 (25)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Sun et al. 2016 [24]

42·6 (9·9)

N/A

41·4 (10·0)

53(19.85%)

47 (44%)

N/A

66 (41%)

34 (32%)

N/A

60 (38%)

21·5 (11·7)

N/A

20·7 (11·5)

  1. N/A Not available, N Number, SD Standard deviation